Last updated 13 days ago
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
140 patients around the world
Available in Argentina
The study will last approximately 4-5 years. Screening is required within 35 days prior
to enrollment. For each participant, the total duration of the clinical trial will be
about 69 weeks including screening.
Eli Lilly and Company
6Research sites
140Patients around the world
This study is for people with
Ulcerative colitis
Moderate/severe ulcerative colitis
Requirements for the patient
To 75 Years
All Gender
Medical requirements
- Have had an established diagnosis of UC of ≥3 months in duration before baseline.Have moderately to severely active UC as assessed by the UC disease activity score.Have an inadequate response to, loss of response to, or intolerance to at least one conventional medication including corticosteroids or one advanced therapy including biologics, Janus Kinase (JAK) inhibitors, or sphingosine-1-phosphate (S1P) immunomodulators.Are on a stable dose of certain oral UC medications including corticosteroids.Must meet contraception requirements.
- Have received anti-interleukin (IL)-23p19 or anti-IL-12p40 antibodies in the past.Have experienced a thrombotic event within 24 weeks before baseline.Have a current diagnosis of Crohn's Disease or certain other inflammatory gastrointestinal diseases.Have had certain abdominal surgeries within the past 3 months or are likely to require surgery for UC during the study.Have a history of certain adenomas, dysplasia's, or malignancies.
Sites
CER Instituto Médico - Quilmes, Buenos Aires
CIPREC Centro de Investigación y Prevención Cardiovascular - CABA
Hospital Provincial del Centenario - Rosario, Santa Fe
Centro Médico Privado de Reumatología - San Miguel de Tucumán
Mautalen - Salud e Investigación - CABA
Clínica Privada Independencia - Buenos Aires
SponsorEli Lilly and Company
Conditions
Moderate/severe ulcerative colitis
Requirements
To 75 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06598943
